Learn · Medical Devices
What Changes About Your Insurance Program When You Get FDA Clearance?
FDA clearance turns an investigational device into a commercial product. Clinical trial liability gives way to product liability, and distribution terms shift.
3 min read · Medical Devices · May 25, 2026
Jump to section
FDA clearance converts an investigational device into a commercial product, and that conversion changes the insurance program materially. Clinical trial liability gives way to commercial product liability. Distribution agreements start requiring additional insured endorsements. Recall exposure becomes real. Most device companies treat clearance as a regulatory finish line and miss that it is also the moment their coverage has to be rebuilt. It is a key transition on the funding-and-stage arc in how insurance changes at each funding stage.
Clearance Changes What the Program Is Insuring
Before clearance, the device is studied, not sold. The exposures are bounded by the protocol, the enrolled subjects, and the IRB framework, and the line that answers them is clinical trial liability, the structure described in how a clinical trial reshapes the device insurance program. After clearance and first commercial sale, the exposure becomes open-ended: every unit in the field, used by people outside a controlled study, for the operational life of the product. That is a different risk, and product liability becomes the dominant line, the exposure mapped in products liability for medical device manufacturers.
The mistake is assuming the trial-era program scales to commercial use on its own. It does not. The clinical trial coverage was sized for a regulated activity that ends at clearance, and the commercial program is sized for an exposure that begins there.
Mind the Seam Between Trial and Commercial
The hardest part of the transition is the handoff. Product liability has to attach at first commercial shipment, with a retroactive date aligned to the end of the clinical trial coverage, so no period of exposure falls between the two. A gap at that seam is one of the most common findings in diligence, because the company is focused on the launch and not on the coverage handoff behind it. The same discipline that puts product liability in place before clearance is what closes this seam cleanly.
The practical move is to plan the trial coverage and the commercial program together, so the dates and scopes line up by design rather than being discovered out of order later.
What Else the Commercial Stage Adds
Clearance brings exposures the investigational stage did not carry. Recall becomes a real risk the moment product is in commerce, and the cost of executing a recall is a first-party line separate from product liability, the distinction in what happens to your device insurance in a recall. Distribution agreements with resellers and hospital customers routinely require the manufacturer to add them as additional insureds on the products policy, so the wording has to be drafted against the actual endorsement the policy provides. Cyber and technology errors and omissions scale up for any device with software or connectivity. The fuller picture of the commercial-stage program is in Class II device insurance before commercialization.
D&O often steps up here too, because the clearance event itself can trigger disclosure obligations and the company is usually raising or scaling around the same time. The program that was right for a pre-clearance company is rarely right for a commercial one.
What to Do Now
Treat clearance as a trigger to rebuild the program, not just a regulatory milestone. Before first commercial shipment, confirm product liability attaches with a retroactive date aligned to the trial coverage, add recall expense coverage, review distribution agreements against the additional-insured wording your policy supports, and scale cyber and management liability to the commercial stage. Start the work ahead of launch, because underwriting a commercial program takes time and the worst moment to find a gap is the day the first unit ships.
Before you commercialize, map the transition from investigational to commercial coverage end to end and confirm no exposure falls into the seam. A specialty review through Tower Street Insurance can structure the clearance-stage rebuild so the launch is covered from the first shipment forward.
Related reading
Further coverage on this segment.
Medical Devices
Is Your AI-Powered Medical Device Covered Under Your Current Product Liability Policy?
Medical Devices
Does Your Business Owners Policy Cover a Medical Device Startup?
Medical Devices
How Does a Clinical Trial Affect Your Medical Device Insurance Program?
Coverage review
Have a specific question about your coverage?
A 30-minute structural review of your current coverage. You receive a gap analysis specific to your segment, stage-appropriate benchmarks, and a working document you can use heading into renewal.